Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes
ReadĀ more here
News
Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Read more here
Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase
One Study of Novel NMDA Receptor Antagonist d-Methadone
Read more here
QR Pharma Announces the Appointment of New Chairman and New Board MemberĀ
Read more here
Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
Read more here
Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics
Read More Here
Melior Discovery Awarded SBIR Grant for Studying MLR-1023 Mechanism of Action
Read more here
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
Read more here
Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778
Read more here
Relmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development
Read more here